TNK2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL123385	0.51	15/20
SCHEMBL120432	0.51	15/20
SCHEMBL120433	0.51	15/20
SCHEMBL124143	0.50	15/20
SCHEMBL121733	0.48	15/20
SCHEMBL123466	0.46	15/20
SCHEMBL123604	0.56	14/20
SCHEMBL122300	0.51	14/20
SCHEMBL167539	0.51	14/20
SCHEMBL168111	0.43	14/20
SCHEMBL122891	0.40	14/20
SCHEMBL120357	0.56	13/20
SCHEMBL120665	0.53	13/20
SCHEMBL168781	0.53	13/20
SCHEMBL121795	0.52	13/20
SCHEMBL121796	0.52	13/20
SCHEMBL169774	0.52	13/20
SCHEMBL169775	0.52	13/20
SCHEMBL123357	0.52	13/20
SCHEMBL121511	0.51	13/20

Clinical trials — most relevant to TNK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
Doxycycline in Human Pulmonary Tuberculosis	PHASE2	COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Interleukin-2 Treatment for Wiskott-Aldrich Syndrome	PHASE1	COMPLETED
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2	PHASE1	COMPLETED
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b	PHASE1	COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients	nan	COMPLETED
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib	nan	COMPLETED
Immune Cell Response to Stimuli	nan	RECRUITING
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
The Relation of Microtubule-Associated Protein 2 and Cell Migration	nan	UNKNOWN
Study of the Pathophysiological Mechanisms Involved in Bleeding Events	nan	COMPLETED
Molecular Analysis of Thoracic Malignancies	nan	ENROLLING_BY_INVITATION
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
The Roles of Neutrophil Elastase in Lung Cancer	nan	UNKNOWN
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED
Studying the Role of Circulating Tumor Cell Clusters in Patients With High-risk Early Breast Cancer, Study GALIA	nan	RECRUITING
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a TNK2 binder may also engage these)

Protein	Name	Similarity
O54967	—	1.000	O54967 →
Q17R13	—	1.000	Q17R13 →
Q5U2X5	—	0.998	Q5U2X5 →
Q80XI6	—	0.995	Q80XI6 →
Q66HA1	—	0.993	Q66HA1 →
MAP3K9	Mitogen-activated protein kinase kinase kinase 9	0.993	landscape →
O70405	—	0.992	O70405 →
Q5R7W7	—	0.991	Q5R7W7 →
Q8VDG6	—	0.989	Q8VDG6 →
Q8K330	—	0.988	Q8K330 →
Q5RJI5	—	0.988	Q5RJI5 →
D3ZG83	—	0.988	D3ZG83 →
MAP3K11	Mitogen-activated protein kinase kinase kinase 11	0.988	landscape →
A5D7F8	—	0.988	A5D7F8 →
B2DD29	—	0.988	B2DD29 →
P98083	—	0.988	P98083 →
Q3U1V8	—	0.988	Q3U1V8 →
A0JPN4	—	0.988	A0JPN4 →
MAP3K10	Mitogen-activated protein kinase kinase kinase 10	0.987	landscape →
Q66L42	—	0.987	Q66L42 →
Q96P48	—	0.987	Q96P48 →
P56945	—	0.987	P56945 →
Q9BRR9	—	0.987	Q9BRR9 →
Q3ULB5	—	0.986	Q3ULB5 →
Q76LL6	—	0.986	Q76LL6 →
Q61140	—	0.986	Q61140 →
Q63767	—	0.986	Q63767 →
Q6S5L9	—	0.986	Q6S5L9 →
P59281	—	0.986	P59281 →
Q9QY01	—	0.986	Q9QY01 →